DBV Technologies to Participate at Upcoming Investor Conferences

Rhea-AI Summary

DBV Technologies (DBVT) has announced participation in several virtual investor conferences in September 2021. The events include the Goldman Sachs Eleventh Annual Biotech Symposium on September 7, followed by Citi's 16th Annual BioPharma Virtual Conference on September 8. Additionally, a pre-recorded fireside chat will be made available on September 13 at 7:00 AM ET during the H.C. Wainwright 23rd Annual Global Investment Conference. Investors can access the webcast and replay on the company’s website.

Montrouge, France, August 31, 2021

DBV Technologies to Participate at Upcoming Investor Conferences

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that DBV Technologies’ senior management team will participate in upcoming virtual investor conferences in September.

Goldman Sachs Eleventh Annual Biotech Symposium
Company management will participate in virtual investor meetings on September 7, 2021.

Citi’s 16^th Annual BioPharma Virtual Conference
Company management will participate in virtual investor meetings on September 8, 2021.

H.C. Wainwright 23^rd Annual Global Investment Conference
The pre-recorded fireside chat will be available on demand starting September 13, 2021 at 7:00 AM ET for the duration of the conference.

A webcast of the fireside chat will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/

A replay of the fireside chat will also be available on DBV Technologies’ website after the event.

About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Summit, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com 

Attachment

• PDF Version

FAQ

When will DBV Technologies participate in investor conferences?

DBV Technologies will participate in several virtual investor conferences on September 7 and 8, 2021, and a fireside chat on September 13, 2021.

What is the schedule for DBV Technologies' investor conferences?

DBV's schedule includes the Goldman Sachs Biotech Symposium on September 7, the Citi BioPharma Conference on September 8, and a fireside chat available from September 13.

Where can I find the DBV Technologies fireside chat?

The pre-recorded fireside chat will be available on DBV Technologies' Investors & Media section of their website starting September 13, 2021.

What technology is DBV Technologies developing?

DBV Technologies is developing Viaskin™, an investigational technology platform for immunotherapy, focusing on food allergies.

What is the stock symbol for DBV Technologies on Nasdaq?

The stock symbol for DBV Technologies on Nasdaq is DBVT.